Pyrimidine Derivatives Modulating Gamma-Secretase for Alzheimer's
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease and related conditions associated with β-amyloid deposition lack effective therapeutic options, particularly in modulating γ-secretase activity to reduce neurotoxic Aβ42 production.
Innovation Solution
Development of pyrimidine derivatives that act as γ-secretase modulators, specifically compounds of formula (I), which are synthesized through a process involving Buchwald-type coupling and used to treat Alzheimer's disease, cerebral amyloid angiopathy, and other β-amyloid related disorders by reducing Aβ42 secretion.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If γ-secretase activity is inhibited to reduce Aβ production, then Aβ deposition is reduced, but Aβ42 production is not selectively reduced and shorter less neurotoxic Aβ isoforms are not increased
Solution Approach 1:
The compound selectively modulates γ-secretase activity at specific cleavage sites within the transmembrane domain, preferentially reducing Aβ42 production while preserving or increasing shorter Aβ isoforms. This localized modulation of enzymatic activity achieves differential effects on different Aβ species without complete γ-secretase inhibition
Solution Approach 2:
The compound changes the kinetic parameters of γ-secretase catalysis, altering the enzyme's substrate processing to favor production of shorter Aβ isoforms over Aβ42. This parameter modification enables selective reduction of neurotoxic Aβ42 while maintaining overall Aβ production at therapeutic levels
2Object-affected harmful factors
If selective γ-secretase modulators are developed to reduce Aβ42, then neurotoxic Aβ42 production is reduced, but the complexity of compound design and synthesis increases
Solution Approach 1:
The compound structure is divided into distinct functional domains: a core pyrimidine ring system providing γ-secretase binding, substituted aromatic groups providing selectivity and affinity, and linker regions providing optimal spacing. This segmentation allows systematic optimization of each domain independently to achieve selective Aβ42 reduction
Solution Approach 2:
The compound combines multiple structural elements with different functions into a single molecule: the pyrimidine core for enzyme binding, aromatic substituents for selectivity, and specific side chains for optimal pharmacokinetic properties. This composite structure achieves selective γ-secretase modulation with improved therapeutic profile
3Reliability
If current Alzheimer's disease treatments are used, then symptomatic relief may be achieved, but effective therapeutic options to modulate γ-secretase activity and reduce Aβ42 production are lacking
Solution Approach 1:
The compound acts upstream in the amyloidogenic pathway by modulating γ-secretase activity before Aβ42 can be produced and deposit in plaques. This preliminary intervention prevents the formation of neurotoxic aggregates rather than treating downstream effects, addressing the root cause of Alzheimer's pathology
Data Source
AI summary
The invention provides new pyrimidine compounds having the general formula (I), wherein R1, R2, R3, n, and X are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.